Compassionate Use

Overview

Expanded Access (known as Compassionate Use) allows for patients who meet certain requirements to receive drugs that are not yet approved for treatment and that are still undergoing clinical research.

Explore Tags

Myeloma Treatments

The following is a listing of myeloma treatments associated with this tag.

All Treatments

View all treatments in development for myeloma patients around the US.

Verified Belantamab Mafodotin
Belantamab Mafodotin Blenrep®

Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).

Verified CLR 131
CLR 131

CLR 131 is a phospholipid drug conjugate (PDC) that selectively delivers radiation (a cytotoxic radioisotope called iodine-131) directly to malignant cancer cells. The US Food and Drug Administration (FDA) has granted Cellectar an orphan drug designation for CLR 131.

Verified Melphalan Flufenamide (Melflufen)
Melphalan Flufenamide (Melflufen)

Melphalan Flufenamide (Melflufen) is an investigational peptide-drug conjugate (PDC) that uses specific enzymes that are produced in large amounts by myeloma cells. Once the drug enters the cell, it delivers a toxic payload to attack the cancer cell.

SparkCures Verified Accurate, up-to-date information. Learn more

Early Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.

Verified Belantamab Mafodotin
Belantamab Mafodotin Blenrep®

Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).

Verified CLR 131
CLR 131

CLR 131 is a phospholipid drug conjugate (PDC) that selectively delivers radiation (a cytotoxic radioisotope called iodine-131) directly to malignant cancer cells. The US Food and Drug Administration (FDA) has granted Cellectar an orphan drug designation for CLR 131.

Verified Melphalan Flufenamide (Melflufen)
Melphalan Flufenamide (Melflufen)

Melphalan Flufenamide (Melflufen) is an investigational peptide-drug conjugate (PDC) that uses specific enzymes that are produced in large amounts by myeloma cells. Once the drug enters the cell, it delivers a toxic payload to attack the cancer cell.

SparkCures Verified Accurate, up-to-date information. Learn more

Late Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified Belantamab Mafodotin
Belantamab Mafodotin Blenrep®

Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).

Verified CLR 131
CLR 131

CLR 131 is a phospholipid drug conjugate (PDC) that selectively delivers radiation (a cytotoxic radioisotope called iodine-131) directly to malignant cancer cells. The US Food and Drug Administration (FDA) has granted Cellectar an orphan drug designation for CLR 131.

Verified Melphalan Flufenamide (Melflufen)
Melphalan Flufenamide (Melflufen)

Melphalan Flufenamide (Melflufen) is an investigational peptide-drug conjugate (PDC) that uses specific enzymes that are produced in large amounts by myeloma cells. Once the drug enters the cell, it delivers a toxic payload to attack the cancer cell.

SparkCures Verified Accurate, up-to-date information. Learn more

Myeloma Clinical Trials

The following is a listing of myeloma clinical trials associated with this tag.

All Clinical Trials

View all active clinical trials around the US.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources